AbstractObjectiveThe objective of this review is to provide an overview on the current development of the specific reversal agents for Non-vitamin K Oral Anticoagulants (NOACs).MethodsWe conducted a systematic literature search strategy to identify potential studies on Medline, Embase, and the Cochrane register.ConclusionsThese new reversal agents for NOACs, will help address the unmet need for the management of major or life threatening bleeds, and the management of emergency surgical procedures in patients taking NOACs. It will increase confidence in the use of NOACs; thereby extending treatment to a wider range of patients
Background Non-vitamin K oral anticoagulants have become an appealing alternative treatment for the ...
Background Non-vitamin K oral anticoagulants have become an appealing alternative treatment for the ...
For several decades the vitamin K antagonist oral anticoagulants were the only outpatient therapy th...
Objective: The objective of this review is to provide an overview on the current development of the ...
AbstractObjectiveThe objective of this review is to provide an overview on the current development o...
The non-vitamin K antagonist oral anticoagulants (NOACs) are used for thromboembolic prophylaxis of ...
Non-vitamin K antagonist oral anticoagulants (NOACs) include thrombin inhibitor dabigatran and coagu...
In recent years, non-vitamin K oral anticoagulants (NOACs) have emerged as an alternative to warfari...
In the last few years, a new category of anticoagulants have been developed, the non-vitamin K oral ...
In the last few years, a new category of anticoagulants have been developed, the non-vitamin K oral ...
Oral anticoagulants (OA) are effective drugs for treating and preventing the formation of blood clot...
Oral anticoagulants (OA) are effective drugs for treating and preventing the formation of blood clot...
Oral anticoagulants (OA) are effective drugs for treating and preventing the formation of blood clot...
Oral anticoagulants (OA) are effective drugs for treating and preventing the formation of blood clot...
Introduction Approximately 4–6% of patients treated with oral anticoagulants (OAC) will suffer from ...
Background Non-vitamin K oral anticoagulants have become an appealing alternative treatment for the ...
Background Non-vitamin K oral anticoagulants have become an appealing alternative treatment for the ...
For several decades the vitamin K antagonist oral anticoagulants were the only outpatient therapy th...
Objective: The objective of this review is to provide an overview on the current development of the ...
AbstractObjectiveThe objective of this review is to provide an overview on the current development o...
The non-vitamin K antagonist oral anticoagulants (NOACs) are used for thromboembolic prophylaxis of ...
Non-vitamin K antagonist oral anticoagulants (NOACs) include thrombin inhibitor dabigatran and coagu...
In recent years, non-vitamin K oral anticoagulants (NOACs) have emerged as an alternative to warfari...
In the last few years, a new category of anticoagulants have been developed, the non-vitamin K oral ...
In the last few years, a new category of anticoagulants have been developed, the non-vitamin K oral ...
Oral anticoagulants (OA) are effective drugs for treating and preventing the formation of blood clot...
Oral anticoagulants (OA) are effective drugs for treating and preventing the formation of blood clot...
Oral anticoagulants (OA) are effective drugs for treating and preventing the formation of blood clot...
Oral anticoagulants (OA) are effective drugs for treating and preventing the formation of blood clot...
Introduction Approximately 4–6% of patients treated with oral anticoagulants (OAC) will suffer from ...
Background Non-vitamin K oral anticoagulants have become an appealing alternative treatment for the ...
Background Non-vitamin K oral anticoagulants have become an appealing alternative treatment for the ...
For several decades the vitamin K antagonist oral anticoagulants were the only outpatient therapy th...